Longeveron (LGVN) announced that the United States Patent and Trademark Office has granted a patent covering administration of the Company’s proprietary mesenchymal stem cells for the treatment of female patients with sexual dysfunction and improvement in sexual quality of life. U.S. Patent No. 12,496,316, entitled “Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron granted Canadian patent covering laromestrocel administration
- Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025
- Longeveron granted U.S. patent for administration of MSCs
- Longeveron Announces Resignation of Board Members
- Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments